> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly's Mevidalen Fails Phase 2 Alzheimer's Trial
- URL: https://www.fdaweb.com/lillys-mevidalen-fails-phase-2-alzheimers-trial/
- Published: 2026-11-18T18:13:16.000Z
- Updated: 2026-11-18T18:13:16.000Z
- Author: David McFarland
- Tags: Drugs

Eli Lilly's investigational Alzheimer's disease drug mevidalen (LY3154207) failed to meet the primary efficacy endpoint in the Phase 2 PRESENCE-ALZ trial, according to results presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference in Boston.

The findings provide additional details behind Lilly's October decision to discontinue development of mevidalen for symptomatic Alzheimer's disease after the program failed to meet the company's internal criteria for success.

The randomized, double-blind, placebo-controlled [PRESENCE-ALZ study (NCT06538116)](https://clinicaltrials.gov/study/NCT06538116?ref=fdaweb.com) evaluated the dopamine D1 receptor positive allosteric modulator in 304 patients with mild-to-moderate Alzheimer's disease. Participants received mevidalen at 25 mg or 50 mg daily or placebo for 24 weeks, according to a [report](https://www.neurologylive.com/view/mevidalen-misses-primary-endpoint-phase-2-alzheimer-trial?utm%5Fsource=chatgpt.com) by *NeurologyLive*.

The trial's primary efficacy assessment used the Integrated Alzheimer's Disease Rating Scale (iADRS), which measures cognitive performance and daily functioning. Neither mevidalen dose met the study's prespecified Bayesian efficacy threshold.

The posterior probabilities of achieving at least a two-point treatment benefit on iADRS were 14.0% for the 25-mg dose and 21.2% for the 50-mg dose, substantially below the study's required threshold of greater than 60%.

Safety findings included increases in systolic blood pressure of approximately 8–11 mm Hg during post-dose monitoring. No deaths or major adverse cardiovascular events were reported.

Mevidalen was being investigated as a potential symptomatic treatment for Alzheimer's disease through modulation of dopamine D1 receptor signaling, an approach distinct from amyloid-targeting therapies intended to modify disease progression.

Lilly removed the program from its development pipeline in October.

The results were presented in a CTAD poster titled *Safety and Efficacy of Mevidalen in Alzheimer's Disease: A Phase 2, Randomized, Double-Blinded Trial*, authored by Lilly researchers and collaborators.